B
BioCryst Pharmaceuticals
Biotech & Life Sciences · Durham, United States · Founded 1986 · IPO 1994
BioCryst has over 80 employees spread across their two locations in Birmingham, Alabama and Durham, North Carolina MoreLess
BioCryst Pharmaceuticals focuses on developing innovative oral drugs for rare diseases, with a particular emphasis on hereditary angioedema (HAE). The company leverages a combination of traditional cell biology and medicinal chemistry to create synthetic compounds that target specific proteins to combat diseases. BioCryst serves patients suffering from rare conditions, aiming to enhance their ability to engage in everyday activities. Operating in the biopharmaceutical market, BioCryst's business model revolves around research and development, clinical trials, and eventual commercialization of its drug pipeline. Revenue is generated through the sale of approved drugs and potential licensing agreements. The company's commitment to scientific excellence and patient needs drives its mission to deliver extraordinary treatments. Keywords: rare diseases, oral drugs, hereditary angioedema, synthetic compounds, protein targets, biopharmaceutical, clinical trials, drug pipeline, patient-focused, scientific excellence.
Company overview
BioCryst Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 1986
- Headquarters
- Durham, United States
- Employees
- 617
- Open positions
- 17
- Dealroom signal
- 40.4
- Investment activity
- 1 companies · latest Oct 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
BioCryst Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Apr 2023 | $450M | — | Pharmakon Holdings | ↗ |
| POST IPO EQUITY✓Other financing | Nov 2021 | $350M | — | OMERS Capital Markets · Royalty Pharma | ↗ |
| POST IPO DEBT✓Debt | Dec 2020 | $200M | — | Royalty Pharma · Athyrium Capital Management | — |
| POST IPO EQUITY✓Other financing | Dec 2020 | $125M | — | Royalty Pharma | — |
| POST IPO EQUITYOther financing | May 2020 | $82M | — | Undisclosed | — |
| POST IPO EQUITYOther financing | Nov 2019 | Undisclosed | — | ||
| POST IPO DEBT✓Debt | Feb 2019 | Midcap Financial | — | ||
| GRANT✓Other financing | Sep 2018 | Undisclosed | — | ||
| POST IPO EQUITYOther financing | Sep 2017 | Undisclosed | — | ||
| POST IPO DEBTDebt | Sep 2016 | Midcap Financial | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
BioCryst Pharmaceuticals website traffic
Latest recorded traffic for BioCryst Pharmaceuticals is 27K monthly website visits, up 17.4% over the last three months. BioCryst Pharmaceuticals's team grew 14.5% over the past year.
Hiring
Open positions at BioCryst Pharmaceuticals
Current openings linked to this company in Dealroom.
Comparisons
BioCryst Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
BioCryst Pharmaceuticals investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
BioCryst Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where BioCryst Pharmaceuticals has talent and traffic
team presence
In the news
Latest news about BioCryst Pharmaceuticals
Recent press, funding announcements, and product moves mentioning BioCryst Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about BioCryst Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about BioCryst Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioCryst Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.